CHICAGO (GenomeWeb) – BiomX, a startup focused on microbiome therapeutics via a proprietary microbiome modulation technology platform, said today that it has raised $24 million in Series A venture capital.
OrbiMed, Johnson & Johnson Innovation–JJDC, and Takeda Ventures led the round. Seventure Partners, MiraeAsset, the Japan-Israel Development Fund, and other unspecified European investors also participated, according to Ness Ziona, Israel-based BiomX.